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Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term
survival of breast cancer patients
M Aubele*,1, AK Walch1, N Ludyga1, H Braselmann2, MJ Atkinson3,4, B Luber5, G Auer6, S Tapio3, T Cooke7 and
JMS Bartlett8
1Institute of Pathology, Helmholtz Centre Munich, German Research Centre for Environmental Health, Neuherberg D-85764, Germany; 2Institute of
Molecular Radiation Biology, Helmholtz Centre Munich, German Research Centre for Environmental Health, Neuherberg D-85764, Germany; 3Institute
of Radiation Biology, Helmholtz Centre Munich, German Research Centre for Environmental Health, Neuherberg D-85764, Germany; 4Klinik fu¨r
Strahlentherapie, Technische Universita¨t Mu¨nchen, Ismaninger Strasse 22, Mu¨nchen 81675, Germany; 5Institut fu¨r Pathologie, Technische Universita¨t
Mu¨nchen, Trogerstr. 18, Mu¨nchen 81675, Germany; 6Department of Oncology and Pathology, Karolinska Institute and Hospital, Stockholm S-17176,
Sweden; 7University Department of Surgery, Glasgow Royal Inf irmary, Queen Elizabeth Building, 10 Alexandra Parade, Glasgow G31 2ER, UK;
8Endocrine Cancer Group, Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK
The cytoplasmic tyrosine kinase PTK6 (BRK) shows elevated expression in approximately two-thirds of primary breast tumours, and
is implicated in EGF receptor-dependent signalling and epithelial tumorigenesis. Using immunohistochemistry, we performed a
retrospective study on 426 archival breast cancer samples from patients with long-term follow-up and compared the protein
expression levels of PTK6, the HER receptors, Sam68 (a substrate of PTK6), and signalling proteins including MAP kinase (MAPK),
phosphorylated MAPK (P-MAPK), and PTEN. We show that PTK6 expression is of significant prognostic value in the outcome of
breast carcinomas. In multivariate analysis, the disease-free survival of patients of X240 months was directly associated with the
protein expression level of PTK6 (Pp0.001), but was also inversely associated with nodal status (Pp0.001) and tumour size
(Pp0.01). PTK6 expression in tumour tissue significantly correlated (Pp0.05) with the expression of PTEN, MAPK, P-MAPK, and
Sam68. To investigate whether these correlations may be due to molecular interactions between PTK6 and these proteins, we used
protein extracts from the T47D cell line for immunoprecipitation and western blot analysis. By this, interactions could be
demonstrated between PTK6 and MAPK, P-MAPK, HER2/neu, HER3, HER4, PTEN, and Sam68. On the basis of these results, we
suggest that PTK6 may serve as a future target for the development of novel treatments in breast cancer.
British Journal of Cancer (2008) 99, 1089–1095. doi:10.1038/sj.bjc.6604660 www.bjcancer.com
Published online 9 September 2008
& 2008 Cancer Research UK
Keywords: PTK6 (BRK); breast cancer; prognosis; MAPK; Sam68; PTEN



























































The cytoplasmic protein tyrosine kinase PTK6 (BRK, breast tumour
kinase) was originally cloned from a human metastatic breast
tumour (Mitchell et al, 1994). PTK6 was shown to be overexpressed
in two-thirds of breast carcinomas (Mitchell et al, 1994; Barker et al,
1997; Llor et al, 1999; Born et al, 2005; Aubele et al, 2007; Ostrander
et al, 2007), and expression is elevated in colon tumours and several
cancer cell lines (Barker et al, 1997; Llor et al, 1999; Kamalati et al,
2000; Meric et al, 2002; Derry et al, 2003).
PTK6 possesses sequences with predicted homology with Src
domains (SH3 and SH2) (Kamalati et al, 1996; Zhang et al, 2005),
suggesting interactions with other signalling proteins. On account of
the known involvement of Src in epithelial tumour development and
structural similarities with Src, PTK6 is thought to have a function
in epithelial tumorigenesis (Petro et al, 2004; Zhang et al, 2005).
Several in vitro studies have attempted to identify the physiolo-
gical function and the interaction partners of PTK6. Many of these
suggest a possible involvement of PTK6 in modulating signal
transduction of HER receptor tyrosine kinases (Kamalati et al, 1996,
2000; Chen et al, 2004; Haegebarth et al, 2005; Zhang et al, 2005).
Knockdown of PTK6 decreases proliferation in breast cancer cell
lines (Harvey and Crompton, 2003) and blocks activity of a GTPase,
of ERK5 (extracellular signal-regulated kinase) and p38 mitogen-
activated protein kinase (MAPK), but not Akt (Mitchell et al, 1994;
Barker et al, 1997; Llor et al, 1999; Born et al, 2005; Ostrander et al,
2007). Furthermore, PTK6 phosphorylates STAT3 (signal transducer
and activator of transcription 3; Liu et al, 2006) and STAT 5b,
leading to increased STAT 5b transcriptional activity in several
breast cancer cell lines (Weaver and Silva, 2007).
In recent years, several additional PTK6 substrates have been
identified (Derry et al, 2000; Babic et al, 2004; Haegebarth et al,
2004, 2005). The first reported substrate of PTK6 phosphorylation
was Sam68 (Src-associated in mitosis 68 kDa), and it was shown
that PTK6 negatively regulates its RNA-binding activity (Derry
et al, 2000). This may have an impact on the post-transcriptional
regulation of gene expression.
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Besides these important in vitro findings, PTK6’s function in
vivo remains largely undefined. Very little is known about its
physiological relevance in inducing phosphorylation events, in
particular in tumour tissue. As mentioned above, there is
increasing evidence that PTK6 is involved in EGF receptor
signalling (Kamalati et al, 1996; Born et al, 2005; Zhang et al,
2005). If true, this is a most important finding, as the HER
receptors –in particular HER2/neu –are of therapeutic and prog-
nostic significance in breast cancer (Slamon, 1990; Meric et al,
2002; Hudelist et al, 2003; Witton et al, 2003; Abd El-Rehim et al,
2004; Bianchi et al, 2006). The HER2/neu antibody trastuzumab
induces tumour regression in approximately 30 – 35% of patients
with HER2-amplified metastatic breast cancer (Hsieh and Moasser,
2007), indicating that additional signalling molecules may
influence the biological response to trastuzumab. Cytoplasmic
tyrosine kinases, such as PTK6, containing SH2 and SH3 domains,
are thought to modify receptor tyrosine kinase signalling (Petro
et al, 2004; Zhang et al, 2005).
The data concerning PTK6 expression in tumour tissues are,
so far, very limited. PTK6 was found to be localised in the
nucleus and cytoplasm in normal oral epithelium, and it was
found in perinuclear regions in poorly differentiated oral
squamous carcinomas (Petro et al, 2004). In normal breast
epithelium, PTK6 expression is low or undetectable, but
it is elevated in many breast carcinomas (Petro et al, 2004; Zhang
et al, 2005; Aubele et al, 2007), indicating that PTK6 over-
expression may be related to carcinogenesis. In contrast, high
levels of PTK6 are expressed in some differentiating epithelial
tissues, such as normal gastrointestinal tract, skin (Llor et al, 1999;
Haegebarth et al, 2004), and prostate (Derry et al, 2003). Moreover,
PTK6 expression is associated with the degree of differentiation of
breast tissue as indicated by oestrogen receptor (ER) expression
(Zhao et al, 2003).
As recently reported by us, PTK6 protein expression has
prognostic value in a small set of 105 breast carcinomas (Aubele
et al, 2007), and correlates with the expression of HER receptors
(Born et al, 2005; Aubele et al, 2007). We have extended the study
to a total of 426 patients with a long-term follow-up. As PTK6
seems to be implicated in signalling pathways, we have expanded
our immunohistochemical analysis of PTK6 to its nuclear substrate
Sam68, the signalling molecules MAPK and P-MAPK, and the
tumour suppressor protein PTEN.
MATERIALS AND METHODS
Patients and tumour samples
Immunohistochemical studies were performed on formalin-fixed,
paraffin-embedded tissues from invasive breast carcinomas. The
study comprises 426 patients with a detailed long-term follow-up,
including those cases reported previously (Aubele et al, 2007). Two
hundred forty-four of the tumours were lymph node negative, 182
were node positive, and the majority of the tumours in this study
were o2 cm in size (n¼ 234). The hormone receptor status was
evaluated immunohistochemically. Classification into negative (no
or low) and positive (medium or high staining intensity) revealed
that 311 and 141 tumours were ER positive and progesterone
receptor (PrR) positive, respectively. Histological classification
(WHO 2003) defined 332 tumours as being invasive ductal not
otherwise specified (NOS). The remaining cases were classified as
tubular (14), lobular (47), medullary (2), and others (31). A total of
221 cases were classified as grade 2, 109 cases as grade 3, and 96
cases as grade 1, according to Elston and Ellis (1991).
All patients were surgically treated, and none of the patients
received preoperative treatment. Fifty patients received no post-
operative treatment, whereas adjuvant antihormonal treatment
was administered to 203 patients, radio- and/or chemotherapy to
33 patients, and 140 patients received combined treatment regimes
(radio- and/or chemo- and/or antihormonal treatment).
The median clinical follow-up of patients was 80 months (mean
94, maximum 264 months) with 121 (28%) of the patients
relapsing with distant metastases and/or local recurrence within
the total follow-up period. Ethical approval for the study was
obtained from the Ethics Committee of the medical faculty of the
Technical University of Munich.
Tissue microarrays (TMA)
Tissue microarray construction was performed using the same
quality criteria and methodology as described with a tissue-
arraying instrument (Beecher Instruments Inc., Silver Spring, MD,
USA) (Aubele et al, 2007). 5 mm sections were cut from the TMA
blocks, and both the TMA and punched block were re-examined to
validate representative sampling.
Immunohistochemistry (IHC)
For IHC on the TMA sections, the antibodies for HER1, HER2/neu,
HER3, HER4, and PTK6 were used as described previously (Aubele
et al, 2007). For further immunohistochemical analysis the
following antibodies were applied (Table 1): p44/42 MAP kinase
(Erk1 and Erk2), P-MAPK (detecting p44/42 MAPK phosphory-
lated on Thr202/Tyr204), PTEN (phosphatase and tensin homo-
logue deleted on chromosome 10), and Sam68. Deparaffinisation
of the TMA sections, antigen retrieval, and incubation with the
primary antibody were performed as described (Quintanilla-
Martinez et al, 2003). Staining and counterstaining were performed
by an automated immunostainer (Ventana Medical System,
Tucson, AZ, USA) (Quintanilla-Martinez et al, 2003; Aubele
et al, 2007).
Tissue staining intensities were scored by two independent
observers as described (Witton et al, 2003; Aubele et al, 2007)
using a 4-point scale, where 0¼ no staining, 1¼ light staining,
2¼moderate staining, and 3¼ strong staining. Immuno-
histochemical positivity for Sam68 was scored in percent positive
stained tumor cells.
Cell culture
T47D cells were obtained from the American Type Culture
Collection and maintained in RPMI (Roswell Park Memorial
Institute medium) supplemented with 10% foetal bovine serum
(FBS), bovine insulin (10 mg ml1), and the antibiotics penicillin
and streptomycin (0.25%) at 371C in 5% CO2.
Protein isolation, immunoprecipitation (IP), and western
blot
For physical disruption of the cells, the T47D cell suspension was
sonicated using high-frequency sound waves (3 30 s, power
30%). For protein isolation, the T-PERs Tissue Protein Extraction
Reagent (Pierce, Rockford, IL, USA) was supplemented with
Complete Mini-Protease inhibitor cocktail tablets (Roche, Mannheim,
Germany), Phosphatase Inhibitor cocktail 1þ 2 (Sigma-Aldrich,
Hamburg, Germany), and the extraction was performed according
to the manufacturer’s protocol.
For IP, the Seizes Primary Immunoprecipitation Kit (Pierce,
Rockford, IL, USA) was applied according to the manufacturer’s
protocol with slight modifications. The primary antibody, PTK6,
was coupled to AminoLinks Plus Coupling Gel at 221C for 4 h with
gentle end-over-end mixing. The antigen (protein lysate, 500 mg)
was precipitated at 221C for 1.5 h with gentle end-over-end mixing.
The precipitates were eluted using the ImmunoPures elution
buffer, containing 1% SDS to achieve dissociation of the antigen
from the covalently immobilised antibody. The eluates were
PTK6 and breast cancer prognosis
M Aubele et al
1090
British Journal of Cancer (2008) 99(7), 1089 – 1095 & 2008 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
analysed by western blotting, using a standard concentration of
1 : 1000 of the primary antibody. To confirm the interaction of
PTK6 and MAPK, an inverse IP with the immobilised MAPK-
targeted antibody was carried out, and precipitated PTK6 was
detected by western blot. To show that the interactions are due to
a specific binding with PTK6, and not to an adsorption to beads,
IP without antibody was also performed.
For western blot analysis, 20 mg samples of protein lysate were
resolved by SDS – polyacrylamide gel electrophoresis, and
transferred to nitrocellulose membranes (Schleicher and Schuell,
Dassel, Germany). Proteins were then detected with antibodies
against PTK6, Sam68, HER2/neu, HER3, HER4, PTEN, MAPK, and
phosphorylated MAPK (Table 1). The appropriate peroxidase-
conjugated secondary antibodies (antirabbit NA934V, antimouse
NA931V, 1 : 2000) were obtained from the GE Healthcare (Munich,
Germany).
Statistics
Correlations among the immunohistochemically evaluated
markers, and between markers and clinical parameters, were
examined by Spearman’s rank correlation test. HER1 positivity
was infrequent (only 6% of the cases), and was excluded from
statistical analysis. Survival analysis was performed using
disease-free interval for follow-up periods of 60, 120, and 240
months. The disease-free interval was defined as the interval from
the date of surgery to the first locoregional recurrence and/or
distant metastases.
For univariate survival analysis, Kaplan–Meier curves were
calculated, and differences between strata were tested with the
log-rank w2-value. The multivariate analysis was performed using
Cox proportional hazards regression and a combined stepwise
selection algorithm (SAS Institute, Cary, NC, USA). All parameters
reaching a significance level of Pp0.15 in univariate analysis were
offered to multivariate analysis. In all other tests, statistical
significance was considered proven if Pp0.05.
RESULTS
PTK6 expression, its cooverexpression, and its correlation
with other parameters
Two-thirds (69%, n¼ 293) of the breast carcinomas showed a high
PTK6 expression (IHC 2þ , 3þ ; Table 2). In decreasing order, we
found the overexpression of Sam68 (52%), MAPK (34%), PTEN
(28%), and P-MAPK (in 7% of tumours). Most of these
overexpressing tumours show co-overexpression with PTK6, as
shown in (Table 2). The expression of PTK6 was not significantly
correlated with clinical and histopathological parameters, such as
lymph node status, tumour size, and histological grade or type
(Table 3). Further, no association was found between PTK6
and HER2, HER3, and HER4 receptor expression. A significant
correlation was observed between the expression of PTK6 and the
expression of PTEN (P¼ 0.002), Sam68 (P¼ 0.0008), MAPK
(P¼ 0.01), and phosphorylated MAPK (P¼ 0.001; Table 4).
Prognostic relevance of parameters
Univariate analysis of parameters for a disease-free survival of
patients All clinical, histopathological, and immunohisto-
chemical parameters were analysed for their prognostic relevance
using Kaplan–Meier analysis. A significant inverse correlation
with the disease-free survival of patients was found for lymph node
status (Pp0.0001), tumour size (Pp0.0001), and the histological
grade of tumours (P¼ 0.002). A direct correlation (Pp0.02)
with the disease-free survival of patients was identified for PgR
positivity and expression of HER4, PTK6, and Sam68 (Table 5).
No significant survival effect was observed in univariate analysis
for HER2/neu (0.08), HER3 (0.3), PTEN (0.2), MAPK (0.98), and
P-MAPK (0.7), or for the ER status (0.2; Table 5).
Multivariate analysis Multivariate analysis was used to assess
the influence of markers on the disease-free survival of patients,
Table 2 Frequency of tumours (%) showing overexpression of markers,
and co-overexpression between PTK6 and the other markersa
Highly
expressed (%)
Co-overexpressed
with PTK6
(% of highly expressed)
PTK6 68.9
PTEN 28.4 77.4
Sam68 52.1 73.9
MAPK 33.7 70.3
P-MAPK 6.5 94.4
IHC¼ immunohistochemistry; MAPK¼mitogen-activated protein kinase; Sam68¼
Src-associated in mitosis 68 kDa. aThresholds for overexpression: PTK6, PTEN,
MAKP, and P-MAPK; IHC X2+; Sam68 IHC: X50% positive tumour cells.
Table 1 Sources and dilutions of antibodies used for IHC and western blotting, respectively
Dilution
Antibodies Source IHC WB
PTK6 (BRK; rabbit) C-17(sc 1188), Santa Cruz Biotechnology, Heidelberg, Germany 1 : 100 1 : 5000
PTK6 (BRK; mouse) 5G1 (sc-66003), Santa Cruz Biotechnology, Heidelberg, Germany 1 : 200
HER1 (EGF-R; mouse) 31G7, Invitrogen, Heidelberg, Germany 1 : 50
HER1 (EGF-R; rabbit) H7298, DAKO, Glostrup, Denmark 1 : 50
HER2/neu (ErbB2; rabbit) Hercep testt, K5204, DAKO, Hamburg, Germany Ready for use
HER2/neu (ErbB2; rabbit) A0485, DAKO, Glostrup, Denmark 1 : 6000
HER3 (erbB3; mouse) H3.105.5, Stratech, Suffolk, England 1 : 20
HER3 (erbB3; mouse) 201P506A, Lab Vision Corp. Fremont, CA, USA 1 : 5000
HER4 (erbB4; mouse) H4.77.16, Stratech, Suffolk, England 1 : 20
HER4 (erbB4; rabbit) 4795, Cell Signaling Technology, Beverly, MA, USA 1 : 500
p44/42 MAP kinase (Erk1 and Erk2; rabbit) 4695, Cell Signaling Technology, Beverly, MA, USA 1 : 100 1 : 10000
p44/42 MAP kinase (rabbit) 9102, Cell Signaling Technology, Beverly, MA, USA 1 : 5000
Phosphorylated MAPK (rabbit) 9101, Cell Signaling Technology, Beverly, MA, USA 1 : 100
Phosphorylated MAPK (rabbit) 4376, Cell Signaling Technology, Beverly, MA, USA 1 : 5000
PTEN (rabbit) 9559, Cell Signaling Technology, Beverly, MA, USA 1 : 50 1 : 2000
Sam68 (68 kDa protein; mouse) sc-1238, Santa Cruz Biotechnology, Heidelberg, Germany 1 : 50 1 : 500
IHC¼ immunohistochemistry.
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together with that of the clinicohistopathological parameters. The
stepwise selected parameters for a disease-free survival of patients
of 4240 months were lymph node status (risk factor 2.1), PTK6
expression (0.6), and tumour size (1.6; Table 6).
The prognostic value of key markers appeared to be time
dependent (Aubele et al, 2007). Performing multivariate analysis
for an interval of 60 months, the tumour size (risk factor 1.9),
PTK6 expression (0.6), HER2/neu (1.0), and lymph node status
(1.7) were independently prognostic. At an interval of 120 months,
HER2/neu protein expression was no longer significant. Here, the
stepwise selected parameters were lymph node status (risk factor
2.1), PTK6 expression (0.6), and tumour size (1.5).
The cohorts studied Comparing the primary and the expanded
tumour cohort with histopathological parameters showed that
both cohorts contain different portions of ER- and PrR-positive
tumours. Whereas the primary cohort contains 39% ER- and 33%
PrR-positive tumours, the expanded cohort contains 79% ER- and
32% PrR-positive tumours. No prominent differences between the
Table 3 Correlations between immunohistochemically assessed protein expressions and the clinicohistopathological parameters
Lymph node status Histological grade Histology Tumour size ER PrR
HER2/neu 0.16 o0.0001 0.018 0.19 o0.0001 0.015
0.19 0.11 0.27 0.13
HER3 0.13 0.15 0.3 0.013 o0.0001 0.02
0.06 0.26 0.12
HER4 0.3 0.01 0.1 0.8 o0.0001 0.5
0.13 0.22
PTK6 0.8 0.5 0.9 0.5 0.2 0.0004
0.18
Sam68 0.9 0.9 0.4 0.13 o0.0001 0.1
0.21
PTEN 0.5 0.11 0.4 0.4 0.01 0.01
0.13 0.13
P-MAPK 0.8 0.1 0.7 0.002 0.1 0.03
0.18 0.12
MAPK 0.9 0.8 0.5 0.2 0.06 0.4
ER 0.5 o0.0001 0.8 0.2 o0.0001
0.20 0.27
PrR 0.1 0.02 0.1 0.2 o0.0001
0.12 0.27
ER¼ oestrogen receptor ; MAPK¼mitogen-activated protein kinase; PrR¼ progesterone receptor; Sam68¼ Src-associated in mitosis 68 kDa. For significant correlations, the
P-values are printed in bold, and the rho factors are given. Negative rho factors¼ inverse correlation.
Table 4 Correlations between immunohistochemically assessed markers
HER2/neu HER3 HER4 PTK6 PTEN Sam68 MAPK P-MAPK ER
HER3 o0.0001
0.38
HER4 o0.0001 o0.0001
0.29 0.65
PTK6 0.17 0.8 0.3
PTEN 0.5 0.1 0.4 0.0016
0.17
Sam68 0.07 0.0001 0.0001 0.0008 o0.0001
0.24 0.21 0.18 0.22
MAPK 0.15 0.0018 o0.0001 0.01 0.011 0.033
0.21 0.30 0.15 0.16 0.13
P-MAPK 0.23 0.018 o0.0001 0.001 0.2 0.1
0.17 0.26 0.16
ER o0.0001 o0.0001 o0.0001 0.23 0.01 o0.0001 0.06 0.14
0.26 0.27 0.22 0.13 0.21
PrR 0.015 0.02 0.5 0.0004 0.014 0.11 0.37 0.032 o0.0001
0.12 0.13 0.18 0.13 0.12 0.27
MAPK¼mitogen-activated protein kinase; PrR¼ progesterone receptor; Sam68¼ Src-associated in mitosis 68 kDa. For significant correlations, the P-values are printed in bold,
and the rho factors are given. Negative rho factors¼ inverse correlation.
Table 5 Results from univariate analysis of the single parameters for a
disease-free survival of patients of X240 months
Parameter P-value
Lymph node status (+/) Pp0.0001
Tumour size (p20, 20–40, 440 mm) Pp0.0001
Histological grade P¼ 0.002
Progesterone receptor P¼ 0.02a
Oestrogen receptor P¼ 0.15
HER2/neu P¼ 0.08
HER3 P¼ 0.25
HER4 P¼ 0.028a
PTK6 P¼ 0.001a
Sam68 P¼ 0.018a
MAPK P¼ 0.98
P-MAPK P¼ 0.7
PTEN P¼ 0.18
MAPK¼mitogen-activated protein kinase. Significant P-values are printed in bold.
aHigh expression corresponds to better prognosis.
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cohorts were found in relation to the lymph node status, tumour
size, and the histological grade.
Performing multivariate analyses only with the newly added
cases, the stepwise selected parameters for a disease-free survival
of patients of 4240 months were lymph node status (risk factor
2.3), tumour size (1.6), and PTK6 expression (0.7). This result is
entirely in accordance with the results from the primary and the
expanded cohort.
Proteins coprecipitating with PTK6
To analyse whether significant correlations among the expression
level of different protein markers in tumour tissue are based on
possible complex formation between these proteins, we performed
IP with the PTK6 antibody using the T47D breast cancer cell line.
Subsequent western blot analysis showed that PTK6 coprecipitated
with MAPK, P-MAPK, HER2/neu, HER3, HER4, Sam68, and PTEN
in T47D cell line (Figure 1). These results suggest that the
correlations of IHC staining intensities in tumour tissues may
represent molecular interactions between the corresponding
proteins, as shown in T47D cell line.
DISCUSSION
In this study, we investigated protein expression of the cytoplasmic
protein kinase PTK6 (BRK), the HER receptors, Sam68, PTEN,
MAPK, and P-MAPK in breast carcinomas, and tested the
associations between these markers and patient prognosis. We
show that PTK6 protein expression is a prognostic marker for
disease-free survival, on the basis of the data from a cohort of 426
invasive breast cancer cases. Further, we confirm the time
dependence of the different prognostic parameters. The prognostic
significance of HER receptors was only evident for short time
period (60 months), as published previously, on the basis of the
data from 105 breast carcinomas (Aubele et al, 2007). A similar
time dependence of prognostic markers has also been reported by
Tovey et al (2005) for the progesterone and HER1 – HER3 receptor
expression in breast cancer.
The expression of PTK6 in breast carcinoma tissue was not
associated with clinicohistopathological parameters, confirming
our previous results (Aubele et al, 2007). In another study,
however, PTK6 staining intensities were found to correlate with the
histological grade of 250 breast carcinomas (Ostrander et al, 2007).
Those discrepant findings may be caused by different composi-
tions of the tumour cohorts.
A significant correlation between the protein expressions of
PTK6 and HER2/neu, HER3, and HER4 was recently published
(Aubele et al, 2007). The small cohort of tumour cases (n¼ 105)
used previously was now expanded to include 426 invasive breast
carcinoma cases. The results presented here could not confirm a
previously found significant correlation between PTK6 and HER
receptor expression. This discrepancy in the results may also be
due to differences in the composition of the cohorts. The cohort
studied here contains proportionally more hormone-receptor-
positive tumours. This may influence and change the statistical
results, and is further supported by the novel finding that PTK6
expression correlates directly with the PrR status, which was not
the case in our previous study.
The comparison of protein expression between the markers in
tumour tissue showed that Sam68, PTEN, MAPK, and P-MAPK are
Table 6 Results of the Cox multivariate regression analysis
Parameter P-value Coefficient
Relative
risk
Total interval (4240 months):
Lymph node status (+/) 0.0003 0.85 2.34
PTK6 expression 0.0058 0.42 0.66a
Tumour size
(10, 10 – 20, 420 mm)
0.01 0.41 1.52
Total Pp0.0001
Interval, 120 months:
Lymph node status (+/) 0.0004 0.84 2.32
PTK6 expression 0.011 0.40 0.67a
Tumour size
(10, 10 – 20, 420 mm)
0.013 0.41 1.50
Total Po0.0001
Interval, 60 months:
Tumour size
(10, 10 – 20, 420 mm)
0.0013 0.61 1.84
Lymph node status (+/) 0.011 0.75 2.11
HER2/neu expression 0.024 0.0035 1.004
PTK6 expression 0.045 0.384 0.681a
Total Po0.0001
The summary of stepwise selected parameters is given for a disease-free survival of
4240 months, 120 months, and 60 months. Positive coefficients increase and
negative coefficients reduce the risk of an event. aHigh expression corresponds to
better prognosis.
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Figure 1 PTK6 coprecipitates with several signalling molecules in human breast cancer cell line, T47D (The specifity of single bands was proven using total
cell lysates and western blot). (A) IP using the (rabbit) PTK6 antibody was analysed by western blot with rabbit antibodies specific for PTK, MAPK, P-MAPK,
PTEN, HER2, and HER4, and mouse antibodies specific for Sam68 and HER3. (B) Inverse IP using rabbit antibody specific for MAPK was analysed by western
blot with rabbit antibody specific for PTK6. IPs using rabbit IgG (sc-2027, Santa Cruz Biotechnology) and mouse PTK6 antibodies were analysed by western
blot with the rabbit PTK6 antibody. No signals were detected by western blot after IP with the rabbit PTK6 antibody, which was blocked by PTK6 peptide
(sc-1188P, Santa Cruz Biotechnology).
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all significantly correlated with PTK6 expression. To get an
indication whether these statistical correlations of markers in
tumour tissue may be caused by molecular associations with PTK6,
we used IP and found that Sam68, PTEN, MAPK, and P-MAPK all
coprecipitate with PTK6. Sam68 was originally identified as one of
the major targets for PTK6 (Taylor and Shalloway, 1994; Derry
et al, 2000; Babic et al, 2004; Haegebarth et al, 2004, 2005). It has
been demonstrated that Sam68 is a substrate downstream of the
EGFR (Lukong et al, 2005), and that tyrosine phosphorylation of
Sam68 by PTK6 regulates negatively its RNA-binding activity
(Derry et al, 2000; Babic et al, 2004; Haegebarth et al, 2004; Lukong
et al, 2005). In our study, Sam68 expression was significantly
associated with PTK6 and with PTEN expression, and inversely
correlated with the expression of HER3 and HER4. Further, a
direct correlation was identified between Sam68 expression and
the disease-free survival of patients in univariate analysis.
PTEN was selected for our immunohistochemical study, because
loss of PTEN expression showed correlation with disease-related
death, lymph node metastasis (Depowski et al, 2001), and
development of distant metastases in 88 tumour samples
(Piekarski and Biernat, 2006). Positive PTEN expression in breast
cancer tissue was associated with low tumour grade, longer
survival time, and ER positivity (Winter et al, 2007). In our study,
PTEN expression was correlated with the expression of PTK6 and
with PrR and ER, confirming the results from Winter et al (2007).
The association between PTK6 and PTEN expression in tissue
corresponds to the coprecipitation of these proteins in the T47D
cell line, indicative for a molecular association or complex
formation of markers. The physiological meaning of this asso-
ciation must be analysed in more detail in future in vitro studies.
No association could be identified between PTEN and the patients’
prognosis, lymph node status, or tumour size.
Mitogen-activated protein kinase is known to be activated by
HER receptors and to promote proliferation. Knockdown of
PTK6-reduced proliferation (Harvey and Crompton, 2003) and
Heregulin- and EGF-induced activation of Rac GTPase, ERK5,
and MAPK (Ostrander et al, 2007). Gutierrez et al (2005)reported
that high levels of active phosphorylated MAPK (p38MAPK)
strongly correlated with upregulated HER2 and increased tamo-
xifen resistance in clinical specimens. In our study, we found
a significant correlation between P-MAPK expression and the
expression of PTK6, HER3, and HER4, but not with HER2.
We further found a correlation between PTK6 expression and the
levels of MAPK and P-MAPK in tumour tissues. A significant
association, however, was found for PTK6, but not for MAPK or
P-MAPK with patients’ disease-free survival.
Although several interaction partners of PTK6 have been
identified in cellular cultures, the signalling function of PTK6 as
well as its function in breast cancer development and prognosis
remains unclear. It is well accepted that the HER receptors
transduce signals through associations with a variety of cyto-
plasmic target proteins containing SH2 and/or SH3 domains. PTK6
possesses both SH2 and SH3 domains (Kamalati et al, 1996; Zhang
et al, 2005), and there is every reason to believe that it participates
in HER receptor signalling processes. According to the current
state of knowledge, however, association partners of PTK6 have
been identified from all three main signal transduction pathways.
It interacts and negatively regulates Akt (Kamalati et al, 2000;
Zhang et al, 2005; Haegebarth et al, 2006). In addition, here, we
could show that also PTEN, which belongs to the same PI3K/Akt
signalling pathway, coprecipitates with PTK6 in T47D cell line, and is
statistically associated with the expression of PTK6 in tumour tissue.
PTK6 influences the MAPK pathway (as described above), and there
is evidence that STATs are also physiological targets of PTK6 (Liu
et al, 2006; Weaver and Silva, 2007). This obvious involvement of
PTK6 in all three signalling pathways may be explained to some
extent by cross talk between pathways. Moreover, PTK6 may
function in post-transcriptional regulation of gene expression and
through modulating the utilisation of messenger RNAs (Harvey and
Crompton, 2004), thus influencing post-transcriptional activity of
many other proteins. Therefore, elevated PTK6 expression in tumour
tissue is presumably accompanied by alterations to the expression
levels of multiple other molecules.
In conclusion, in this study, we show that PTK6 protein
expression in 426 breast cancer cases is of high prognostic value,
independent of the classical morphological and molecular markers,
such as lymph node involvement, tumour size, and HER2 status.
Although the role of PTK6 in breast cancer development and
prognosis is not known, these results are of important clinical
relevance as PTK6 may be a potential future target for the develop-
ment of novel treatments for breast cancer. On the basis of this data
and other expression studies, there is compelling reason to further
investigate the cellular function and interaction pathways of PTK6.
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